Japanʼs Ministry of Health, Labour and Welfare issued marketing authorization for the drug to Richterʼs local license partner Mochida Pharmaceutical in September.

The European Commission approved teriparatide in January 2017 and the product was launched in Europe, under the brand Terrosa, in August 2019, after the patent of the reference product expired.